Cody Ashby

High Impact

Assistant Professor

University of Arkansas for Medical Sciences

faculty

24 h-index 185 pubs 3,571 cited

Research Areas

Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Immune Response and Inflammation Cancer Genomics and Diagnostics Epigenetics and DNA Methylation Cancer Immunotherapy and Biomarkers Protein Structure and Dynamics Health Sciences Research and Education

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Cody Ashby's research focuses on the molecular and evolutionary mechanisms underlying multiple myeloma and other B cell malignancies. His work investigates how genetic alterations, such as chromothripsis, and epigenetic changes, like the hijacking of super-enhancers, contribute to tumor development and progression. Ashby has also explored the role of specific proteins, such as TRIP13, in modulating protein deubiquitination and accelerating cancer development, and how CST6 can suppress osteolytic bone disease associated with multiple myeloma.

Further investigations by Ashby examine the immune microenvironment in multiple myeloma and its precursor stages using multi-omics approaches. His recent publications also include work on novel therapeutic strategies, such as bispecific BCMA/CD24 CAR-T cells for controlling multiple myeloma growth. Ashby is a highly cited researcher with a significant publication record and collaborates extensively with colleagues at the University of Arkansas for Medical Sciences.

Metrics

h-index: 24
Publications: 185
Citations: 3,571

Selected Publications

How Does Age at Diagnosis Influence Multiple Myeloma Survival? Empirical Evidence (2025) DOI
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025) DOI
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024) DOI
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024) DOI
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024) DOI
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease (2023) DOI
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023) DOI
Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems (2023) DOI
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma (2023) DOI
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023) DOI
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023) DOI